Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2J2 | P51589 | 2/20 | 0.43 |
| ▸ | CFD | P00746 | 3/20 | 0.42 |
| ▸ | KLK7 | P49862 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 2/20 | 0.39 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3289653 | 0.93 | EPHX2 (0.42) | EPHX2CYP2C9CYP2J2CFDKLK7 | |
| SCHEMBL5144228 | 0.92 | EPHX2 (0.45) | EPHX2CYP2C9 | |
| SCHEMBL3290908 | 0.91 | NAMPT (0.42) | EPHX2CYP2C9CYP2J2CFDKLK7 | |
| SCHEMBL3295798 | 0.91 | SLC5A7 (0.44) | EPHX2CYP2C9CYP2J2CFDKLK7 | |
| SCHEMBL5142098 | 0.89 | KMT2A (0.45) | EPHX2CYP2C9PRKAA2 | |
| SCHEMBL3290058 | 0.89 | CFD (0.42) | EPHX2CYP2C9CYP2J2CFD | |
| SCHEMBL5144180 | 0.89 | PRKAA2 (0.41) | EPHX2CFDKLK7PRKAA2 | |
| SCHEMBL3289178 | 0.89 | EPHX2 (0.45) | EPHX2CYP2C9CYP2J2CFDKLK7 | |
| SCHEMBL3289992 | 0.88 | EPHX2 (0.46) | EPHX2CYP2C9CFDPRKAA2 | |
| SCHEMBL5143816 | 0.88 | PRKAA2 (0.41) | CFDKLK7PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | MERCK PATENT GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254919-A1 | Aroyl-O-Piperidine Derivatives for the Treatment of Diabetes-Related Problems | GPR119, FABP4, LIPC | EPHX2 1594/4885CYP2C9 730/4885CYP2J2 997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.